14:31:30 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaOAX Equities
SektorHälsovård
IndustriBioteknik
Aqua Bio Technology är ett norskt bolag verksamma inom kosmetikabranschen. Bolaget utvecklar, tillverkar och kommersialiserar ingredienser som används inom ett flertal kosmetiska produkter världen över. Störst verksamhet återfinns inom lösningar för hudvårdsprodukter. Merparten av bolagets produkter säljs på en global marknad via diverse distributörer. Bolaget grundades 2004 och har sitt huvudkontor i Lysaker.

Kalender

2020-08-26 Kvartalsrapport 2020-Q2
2020-06-11 Ordinarie utdelning ABT 0.00 NOK
2020-06-10 Årsstämma 2019
2020-04-15 Bokslutskommuniké 2019
2019-08-28 Kvartalsrapport 2019-Q2
2019-06-06 Ordinarie utdelning ABT 0.00 NOK
2019-06-05 Årsstämma 2018
2019-04-24 Bokslutskommuniké 2018
2019-01-07 Extra Bolagsstämma 2019
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-30 Årsstämma 2017
2018-02-21 Bokslutskommuniké 2017
2017-08-16 Kvartalsrapport 2017-Q2
2017-06-08 Ordinarie utdelning ABT 1.00 NOK
2017-06-07 Årsstämma 2016
2017-02-15 Bokslutskommuniké 2016
2016-11-18 Bonusutdelning ABT 1.00 NOK
2016-11-17 Extra Bolagsstämma 2016
2016-11-17 Kvartalsrapport 2016-Q3
2016-08-17 Kvartalsrapport 2016-Q2
2016-06-09 Ordinarie utdelning ABT 1.50 NOK
2016-06-08 Årsstämma 2015
2016-05-11 Kvartalsrapport 2016-Q1
2016-02-10 Bokslutskommuniké 2015
2015-11-18 Kvartalsrapport 2015-Q3
2015-08-19 Kvartalsrapport 2015-Q2
2015-06-04 Ordinarie utdelning ABT 1.00 NOK
2015-06-03 Årsstämma 2014
2015-05-13 Kvartalsrapport 2015-Q1
2015-02-11 Bokslutskommuniké 2014
2014-11-26 Kvartalsrapport 2014-Q3
2014-08-20 Kvartalsrapport 2014-Q2
2014-06-11 Årsstämma 2013
2014-05-21 Kvartalsrapport 2014-Q1
2014-02-12 Bokslutskommuniké 2013
2013-11-27 Kvartalsrapport 2013-Q3
2013-08-21 Kvartalsrapport 2013-Q2
2013-06-13 Kapitalmarknadsdag 2013
2013-06-12 Ordinarie utdelning
2013-06-11 Årsstämma 2012
2013-05-22 Kvartalsrapport 2013-Q1
2013-02-13 Bokslutskommuniké 2012
2012-11-27 Kvartalsrapport 2012-Q3
2012-08-28 Kvartalsrapport 2012-Q2
2012-06-14 Årsstämma 2011
2012-05-23 Kvartalsrapport 2012-Q1
2012-02-17 Bokslutskommuniké 2011
2011-11-30 Kvartalsrapport 2011-Q3
2011-08-29 Kvartalsrapport 2011-Q2
2011-06-17 Ordinarie utdelning
2011-06-16 Årsstämma 2010
2011-05-30 Kvartalsrapport 2011-Q1
2011-02-18 Bokslutskommuniké 2010
2019-09-02 08:00:14
Reference is made to the stock exchange notice of Aqua Bio Technology ASA ("ABT"
or the "Company") published on 28 August 2019 regarding exercise of warrants by
certain primary insiders.

As set out in that primary insider notice, Chairman of the Board Edvard Cock
(through Blixen Invest AS) exercised 500,000 warrants and Board member Roger
Hofseth (through Finnvik Eiendom AS) exercised 1,500,000 warrants. Upon such
exercise and following expiry of the exercise period for the warrants, both
Blixen Invest AS and Finnvik Eiendom AS surpassed thresholds for mandatory
notification of ownership:

  * Blixen Invest AS will receive 500,000 new shares in the Company following
    exercise of warrants. Prior to such exercise, Blixen Invest AS hold 500,000
    shares and votes in the Company, corresponding to 4.25% of the shares and
    votes outstanding in the Company as of today. Following such exercise,
    Blixen Invest AS will hold 1,000,000 shares and votes in the Company
    corresponding to 6.5% of the total outstanding shares and votes in the
    Company (calculated after issuance of the new shares after exercise of
    warrants).

  * Finnvik Eiendom AS will receive 1,500,000 new shares in the Company
    following exercise of warrants. Prior to such exercise, Finnvik Eiendom AS
    hold 2,187,000 shares and votes in the Company, corresponding to 18.79% of
    the shares and votes outstanding in the Company as of today. Following such
    exercise, Finnvik Eiendom AS will hold 3,687,000 shares and votes in the
    Company corresponding to 23.99% of the total outstanding shares and votes in
    the Company (calculated after issuance of the new shares after exercise of
    warrants).


This information is subject to the disclosure requirements pursuant to sections
4-3 and 5-12 of the Norwegian Securities Trading Act.